Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy
Year: 2013
Type: article
Abstract: INTRODUCTION: Complete suppression of viral replication is crucial in chronic HCV treatment in order to prevent relapse and resistance development. We wanted to find out which factors influence the period from being already HCV RNA negative by bDNA assay (< 615 IU/mL) to become undetectable by the more sensitive TMA test (< 5.3 IU/mL). MATERIAL AND METHODS: Evaluated were 433 HCV type 1-infected patients. All of them received 1.5 ug/kg Peg-IFNα-2b plus ribavirin for 18-48 weeks. bDNA was performed weekly during the first 8 weeks and thereafter at weeks 12, 24, and 48. Patients who became bDNA undetectable were additionally analysed by TMA. RESULTS: Of the 309 patients with on-treatment response (< 615 IU/mL), 289 also reached undetectable HCV RNA levels by TMA. Multivariate analysis revealed that viremia ≤ 400,000 IU/mL (p = 0.001), fast initial virologic decline (p = 0.004) and absence of fibrosis (p = 0.035) were independent predictors of an accelerated on-treatment response by TMA assay in already bDNA negative patients. bDNA negative patients becoming HCV RNA undetectable by TMA within the following 3 weeks had a frequency of relapse of 21%, whereas those showing TMA negativity after 3 weeks relapsed in 38% (p = 0.001). In RVR patients (bDNA < 615 IU/mL at week 4) the corresponding relapse rates were 15.3% vs. 37.5%, respectively (p = 0.003). CONCLUSION: Early viral kinetics, baseline viremia and fibrosis stage are important tools to predict persistent minimal viremia during interferon-based therapy. The data have implications for designing a more refined treatment strategy in HCV infection, even in the setting of protease inhibitor-based triple treatment.
Source: Annals of Hepatology
Institutions: Goethe University Frankfurt, University Hospital Frankfurt, Charité – Universitätsmedizin Berlin, University of Würzburg, Universitätsklinikum Würzburg, University Medical Center Freiburg, University Hospital Bonn, Asklepios Klinik St. Georg, Institute for Interdisciplinary Medicine, Stiftung Charité, University Hospital Leipzig
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,500
Awards: Verbundprojekt: 'Suszeptibilität bei Infektionen: HCV' - Genetische Varianten der Regulatoren von angeborener Immunität als Empfänglichkeitsfaktoren in der HCV-Infektion, G5285913679, Verbundprojekt: Suszeptibilität bei Infektionen: HCV - Genetische Varianten der Regulatoren von angeborener Immunität als Empfänglichkeitsfaktoren der HCV - Infektion, Verbundprojekt: Kompetenznetz Infektionskrankheiten Hepatitis (Hep-Net): Teilprojekt 10.1.4: Charakterisierung viraler genomischer Sequenzen
OpenAlex ID: W2097911020
